Home World News Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer World News Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 606 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Addressing Common Concerns Around Taking Opioids for Cancer-Related Pain: An Expert... July 5, 2023 Contact January 18, 2019 FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single... June 20, 2025 FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumours... October 29, 2020 Load more HOT NEWS How I Learned to Advocate for Myself During Cancer: “Your Stories”... Όροι χρήσης και προϋποθέσεις Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk... Presence of Tumour and Higher Levels of LAG3-positive T-cells in the...
